The overall survival is good with both surgical options, and even calves with liver involvement and septic arthritis associated can be successfully treated with a combination of long term antibiotics and umbilical vein marsupialization.
Antimicrobial resistance (AMR) is an important burden for public health and veterinary medicine. For Québec (Canada) dairy farms, the prevalence of AMR is mostly described using passive surveillance, which may be misleading. In addition, the presence of extended spectrum β-lactamase (ESBL)/AmpC producing Escherichia coli is unknown. This observational cross-sectional study used random dairy farms (n = 101) to investigate AMR and extended spectrum β-lactamase (ESBL)/AmpC producing Escherichia coli. Twenty antimicrobials were tested on E. coli isolates (n = 593) recovered from fecal samples (n = 599) from calves, cows, and the manure pit. Isolates were mostly susceptible (3% AMR or less) to the highest priority critically important antimicrobials in humans. The highest levels of AMR were to tetracycline (26%), sulfisozaxole (23%) and streptomycin (19%). The resistance genes responsible for these resistances were, respectively: tet(A), tet(B), sul1, sul2, sul3, aph(3”)-Ib (strA), aph(6)-Id (strB), aadA1, aadA2, and aadA5. ESBL analysis revealed two predominant phenotypes: AmpC (51%) and ESBL (46%) where blaCMY−2 and blaCTX−M(blaCTX−M−1, blaCTX−M−15, and blaCTX−M−55) were the genes responsible for these phenotypes, respectively. During this study, 85% of farms had at least one ESBL/AmpC producing E. coli. Isolates from calves were more frequently resistant than those from cows or manure pits. Although prevalence of AMR was low for critically important antimicrobials, there was a high prevalence of ESBL/AmpC-producing E. coli on Quebec dairy farms, particularly in calves. Those data will help determine a baseline for AMR to evaluate impact of initiatives aimed at reducing AMR.
OBJECTIVE
To describe the clinical and clinicopathologic characteristics, treatment, and outcome for cattle that developed a retroperitoneal abscess (RA) following paralumbar fossa laparotomy (PFL).
ANIMALS
32 Holstein cows with RA.
PROCEDURES
The record database of a veterinary teaching hospital was searched to identify cattle that were treated for an RA between January 1995 and March 2017. Cattle with an RA > 30 cm in diameter located 3.5 cm subjacent to the skin that had undergone a PFL < 3 months before examination for the RA were evaluated. Information extracted from the record of each cow included signalment; physical examination, clinicopathologic, and transabdominal ultrasonographic findings; treatments administered; and outcome. Milk production data were analyzed for the lactations before, during, and after RA treatment.
RESULTS
Common physical examination findings were rumen hypomotility, anorexia, and fever, and common clinicopathologic findings were anemia and neutrophilia. Abdominal palpation per rectum and transabdominal ultrasonography facilitated RA diagnosis and identification of the optimal location for drainage. Thirty of 32 cows underwent surgical drainage of the RA and prolonged administration of systemic antimicrobials. Two cows were euthanized because of concurrent peritonitis, including 1 that underwent surgical RA drainage. Thirty cows were discharged from the hospital alive, and most returned to their previous level of milk production.
CONCLUSIONS AND CLINICAL RELEVANCE
Although uncommon, RA should be suspected in cows that develop anorexia and fever within 3 months after PFL. Cows with RA often returned to their previous level of milk production, but treatment was generally prolonged and costly.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.